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Abstract: Exhaled breath analysis holds great promise as a diagnostic and investigative tool 
in COPD and is a new and rapidly expanding ﬁ  eld of research in pulmonary disease. Generally 
speaking, exhaled breath analysis focuses on two areas: measurement of exhaled nitric oxide 
(ENO) and the detection of biomarkers in exhaled breath condensate (EBC). ENO measurement 
may not be as useful in COPD as in other pulmonary diseases, such as asthma, due to the lower 
levels of ENO found in COPD, although this is an area of ongoing research. Analysis of EBC 
for proinﬂ  ammatory biomarkers is an area of great promise but its true value will not be real-
ized until methods of collecting and analyzing EBC have been standardized. Once this is done, 
biomarkers detected in EBC may assist in the diagnosis of COPD, identiﬁ  cation of preclinical 
disease, phenotyping of COPD patients, evaluation of response to therapies and deﬁ  ning the 
prognosis of individual patients. Identiﬁ  cation of novel inﬂ  ammatory mediators in EBC may 
cast new light on the pathogenesis of COPD and identify new therapeutic targets, which are 
badly needed in this disease.
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Introduction
There is considerable interest in the use of biomarkers in chronic obstructive pulmonary 
disease (COPD) (Barnes et al 2006). Potential uses of biomarkers in COPD are many. 
Biomarkers could assist in the diagnosis of COPD, in dividing COPD patients into 
different phenotypic groups, in evaluating response to treatment and in deﬁ  ning the 
prognosis of individual patients. Biomarkers could also be a powerful research tool in 
COPD, identifying novel pathways of COPD pathogenesis. However, the measurement 
of biomarkers in COPD is difﬁ  cult for several reasons. Biomarkers detected in serum 
or urine may not represent events in the lung but the lung itself is difﬁ  cult to sample 
directly. Traditional methods of sampling the lung include bronchoalveolar lavage 
(BAL), transbronchial biopsy and sputum analysis, which are costly and involve risks 
to subjects. Sputum analysis requires numerous processing steps to remove mucus 
and other debris which may affect the detection of volatile intermediates. In contrast, 
exhaled breath analysis is safe, non-invasive and inexpensive and requires little or no 
processing. It is simpler than induced sputum collection, involving no more than tidal 
breathing into a collection device.
COPD is a difﬁ  cult disease to study clinically. Commonly used endpoints in 
clinical trials, such as exacerbations or decline in forced expiratory volume in one 
second (FEV1) are infrequent or change little over time. Clinical trials of interven-
tions in COPD must enroll hundreds of patients and continue for years in order to 
demonstrate differences between control and treatment groups. For this reason, 
identiﬁ  cation of biomarkers, that could be used as surrogate endpoints in clinical 
trials, has been identiﬁ  ed as a priority by the National Institutes of Health (Croxton 
et al 2002). Although the diagnosis of COPD is usually clear, distinguishing COPD 
from other obstructive diseases, particularly asthma, can be difﬁ  cult. The presence of 
irreversible airﬂ  ow obstruction is central to the deﬁ  nition of COPD but many COPD International Journal of COPD 2007:2(4) 404
O’Reilly and Bailey
patients demonstrate signiﬁ  cant reversibility of their airﬂ  ow 
obstruction with inhaled bronchodilators and the degree of 
reversibility may change considerably between evaluations 
(Calverley et al 2003; NHLBI 2005). Patients with asthma 
can also develop irreversible airﬂ  ow limitation (NAEPP 
2006). For these reasons, bronchodilator reversibility testing 
cannot reliably distinguish asthma from COPD and there 
is no diagnostic test that can distinguish between asthma 
and COPD in all cases. New diagnostic tests, involving 
biomarkers of inﬂ  ammation, might aid in distinguishing 
between these two diseases by detecting differences in air-
way inﬂ  ammation between patients with asthma and COPD 
(Fabbri et al 2003). Biomarkers of airway inﬂ  ammation in 
exhaled breath might aid in the early diagnosis of COPD 
before symptoms or changes in spirometry are present and 
may help to identify those smokers at risk of developing 
the disease. This would be a signiﬁ  cant advance as most 
people with COPD are diagnosed late in their disease, when 
available therapeutic and preventive measures are limited. 
Biomarkers could help identify different phenotypes of 
COPD patients who might respond differently to therapeutic 
interventions such as inhaled corticosteroids and long-term 
oxygen therapy (Croxton and Bailey 2006). Identiﬁ  cation of 
novel biomarkers in exhaled breath could cast light on the 
inﬂ  ammatory pathways important in COPD pathogenesis 
and identify potential targets for new therapies.
Identiﬁ  cation of biomarkers in exhaled breath in lung 
disease has generally involved two different approaches: 
measurement of exhaled nitric oxide (ENO) and identiﬁ  cation 
of water-soluble biomarkers in exhaled breath condensate 
(EBC). Of these two approaches, ENO analysis is the more 
studied and better standardized and is approaching clini-
cal use in the diagnosis and management of chronic lung 
diseases.
Use of ENO in COPD
Nitric oxide (NO) is a gaseous free radical which is important 
in many biological processes in lung physiology and is pro-
duced by many different cell types, including epithelial cells, 
endothelial cells, neurons and inﬂ  ammatory cells in the lung 
(Gaston et al 1994). NO is generated in cells by nitric oxide 
synthases of which there are three isoforms (Moncada et al 
1991). Chronic, low-level production of NO in the lung by 
epithelial cells and endothelial cells causes bronchodilation 
and vasodilation by directly causing smooth muscle relax-
ation. NO acts as a neurotransmitter in the non-cholinergic, 
non-adrenergic nervous system in the lung which mediates 
bronchodilation. It is also produced by inﬂ  ammatory cells in 
the airways, particularly macrophages, where it is important 
in the generation of reactive species important in pathogen-
killing (Hickman-Davis et al 2002) and tissue injury in inﬂ  am-
mation (Haddad et al 1994). The nitric oxide synthase found 
in inﬂ  ammatory cells is inducible by pro-inﬂ  ammatory cyto-
kines. This means that large amounts of NO may be produced 
in the airways in inﬂ  ammatory lung diseases and may be 
measured in exhaled breath. NO can be easily measured 
in exhaled air in patients with asthma where levels in excess 
of 100 ppb (parts per billion) can be measured compared to 
20 ppb in healthy controls. ENO correlates with asthma 
activity and severity and has been used as part of a chronic 
asthma management program in children (Smith et al 2005). 
ENO is quickly and reproducibly measured by tidal breathing 
into a meter where ENO levels are instantaneously measured 
by chemiluminescence. Methods for the measurement of 
ENO have been standardized and published by the American 
Thoracic Society (ATS 1999). This has enabled ENO analysis 
to become a widely adopted clinical and research tool in 
respiratory disease.
The situation in COPD is less clear-cut. Several studies 
have demonstrated higher levels of ENO in COPD patients 
compared to controls. In these studies, ENO has been dem-
onstrated to correlate with disease severity in COPD, to 
increase further during exacerbations and to decline after 
treatment with inhaled corticosteroids (Maziak et al 1998; 
Agusti et al 1999; Corradi et al 1999; Montuschi et al 2001). 
Other studies of ENO in COPD have not demonstrated el-
evated levels compared to controls (Clini et al 1998; Rutgers 
et al 1999). ENO has also been demonstrated to correlate 
both positively (Maziak et al 1998; Corradi et al 1999) and 
negatively (Clini et al 1998) with FEV1 in COPD, perhaps 
reﬂ  ecting its dual role in the lung as a pro-inﬂ  ammatory 
molecule and bronchodilator. These conﬂ  icting results may 
be due to a number of factors. Elevation of ENO in COPD 
is modest and not at all of the magnitude seen in asthma. 
Studies of ENO in COPD have involved small numbers of 
subjects and have employed different methods of measur-
ing ENO. Some studies included current smokers who have 
much lower ENO levels than ex-smokers, perhaps due to 
reaction of NO in the airways with molecules present in 
cigarette smoke or to inhibition of NO synthases (Kharitonov 
et al 1995). Nonetheless, there are potential uses for ENO 
analysis in the management of COPD. ENO might aid in the 
differential diagnosis of asthma and COPD as much higher 
levels of ENO are found in asthmatics. Existing data suggest 
that COPD patients with eosinophilic airway inﬂ  ammation or 
with greater bronchodilator reversibility have higher levels International Journal of COPD 2007:2(4) 405
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of ENO (Chanez et al 1997; Papi et al 2000). Such patients 
might be more likely to respond to treatment with inhaled 
corticosteroids. ENO levels might both identify these patients 
and detect a response to treatment. COPD patients with 
pulmonary hypertension and cor pulmonale may have lower 
ENO levels, perhaps due to impaired endothelial release of 
this vasodilator mediator (Clini et al 2000), and this might 
help identify those COPD patients who would beneﬁ  t from 
long-term oxygen treatment (Croxton and Bailey 2006). 
Answering these questions will require studies involving 
larger numbers of ex-smoking COPD patients.
Use of EBC in COPD
EBC collection is a promising non-invasive method for 
sampling the lower airways. EBC collection simply involves 
tidal breathing into a chilled collection device. Water vapor in 
exhaled breath is condensed and collected and various media-
tors can be then be quantiﬁ  ed in the condensate. Mediators 
of interest are thought to be derived from droplets of airway 
epithelial lining ﬂ  uid (ELF) which are mobilized from the 
lower airways by convection during expiration (Effros et al 
2002). Numerous inﬂ  ammatory mediators have been detected 
in EBC in several lung diseases, including asthma, COPD and 
the acute respiratory distress syndrome. Mediators ranging in 
size from simple pro-oxidant molecules to proteins have been 
detected. Although EBC analysis is a promising technique, 
there are many methodological questions associated with 
it that have precluded its adoption as a widespread clinical 
test. Different investigators have used many different types 
of apparatus for collecting EBC including Teﬂ  on tubing, ice 
baths and convection cylinders. Before EBC analysis can 
become main-stream, a standardized method of collecting 
EBC will have to be adopted. Commercially produced EBC 
collection devices are becoming available that may assist 
this process, such as the R tube® (Respiratory Research) and 
Ecoscreen® device (Viasys) (Montuschi 2005). The ques-
tion of dilution is also a signiﬁ  cant problem. Respiratory 
droplets mobilized into exhaled air are diluted in the large 
volume of water already present in exhaled breath, which 
is water-saturated. The dilution factor is extremely large 
and been estimated to be as high as 10,000 fold (Effros et al 
2002). This causes several problems, including the fact that 
mediators found in EBC are usually present at very low 
concentrations and detectable only at the very limits of avail-
able tests. This is particularly true for proteins which due to 
their size are less likely to become aerosolized in respiratory 
droplets. The degree of dilution may vary between subjects 
and between tests making standardization of this technique 
extremely difﬁ  cult. For example, respiratory parameters 
such as exhaled breath ﬂ  ow rate may affect the mobiliza-
tion of respiratory droplets into exhaled air and greatly 
affect the ﬁ  nal concentration of mediators measured in 
EBC. Addressing these issues will require standardization 
of EBC collection methodology as has been done with ENO. 
Recent guidelines for EBC collection issued by the American 
Thoracic Society and European Respiratory Society address 
these issues and represent an important step in this direc-
tion (Horvath et al 2005). It has been suggested that EBC 
mediator levels can be standardized by measuring levels 
of non-volatile cations in EBC using conductivity (Effros 
et al 2003). This is thought to reﬂ  ect the degree of dilution 
of respiratory droplets as ELF cation levels are thought to 
remain relatively constant. However, in this approach, EBC 
samples are lyophilized to remove ammonia and this process 
may affect biomarker levels. These concerns notwithstand-
ing, EBC analysis has proved to be a surprisingly robust 
technique for investigating lung diseases. In general, studies 
of EBC in COPD have shown clear differentiation between 
patient groups and controls, changes with therapy and good 
reproducibility, illustrating its potential in the investigation 
and management of lung diseases (Montuschi 2005).
Mediators measured in EBC in COPD have ranged from 
simple molecules such as hydrogen peroxide and hydrocar-
bons to larger molecules such as isoprostanes and cytokines. 
Perhaps the most studied EBC mediator in COPD is hydro-
gen peroxide, which is probably derived from superoxide, 
generated by neutrophils in the airways in COPD. Hydrogen 
peroxide is believed to be a biomarker for oxidative stress 
which is thought to be of importance in the pathogenesis 
of COPD (Repine et al 1997). Hydrogen peroxide levels 
have been demonstrated to be higher in EBC of COPD 
patients compared to healthy controls (Nowak et al 1999; 
De Benedetto et al 2000), to rise further during exacerbations 
(Dekhuijzen et al 1996) and to correlate with severity of 
COPD as measured using FEV1 (Kostikas et al 2003). Cur-
rent smoking increases hydrogen peroxide levels in EBC in 
healthy subjects (Nowak et al 2001) but does not appear to 
have this effect in stable COPD (Nowak et al 1999; Kostikas 
et al 2003). Hydrogen peroxide levels in EBC may, therefore, 
reﬂ  ect underlying airway inﬂ  ammation and be an appropri-
ate biomarker for use in larger studies of COPD. Hydrogen 
peroxide levels in EBC were reduced by n-acetylcysteine, 
as anti-oxidant, in COPD patients, reﬂ  ecting its use as a 
biomarker of oxidative stress (Kasielski and Nowak 2001; 
De Benedetto et al 2005). Inhaled corticosteroids were dem-
onstrated to reduce EBC hydrogen peroxide levels in COPD International Journal of COPD 2007:2(4) 406
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patients in one study (van Beurden et al 2003) but not in 
others (Ferreira et al 2001; Kostikas et al 2003). There is a 
need for larger studies to examine the usefulness of measur-
ing hydrogen peroxide in EBC in COPD. Hydrogen peroxide 
would be an appropriate biomarker for airway inﬂ  ammation 
in COPD as levels correlate with neutrophilic inﬂ  ammation 
(Kostikas et al 2003), the predominant cell type in the airways 
in COPD. Hydrogen peroxide is easily measured in EBC 
using inexpensive chemical reagents.
The isoprostanes are prostaglandin-like compounds 
formed from the free radical-initiated peroxidation of ara-
chidonic acid (Morrow and Roberts 1997). Isoprostanes are 
believed to be the most reliable biomarkers of oxidative stress 
in humans. They are chemically stable, are formed in vivo 
and are a reliable marker for lipid peroxidation which is a 
central feature of oxidative stress. Levels are present in de-
tectable amounts in biological ﬂ  uids, allowing the deﬁ  nition 
of a normal range (Roberts and Morrow 2000). One of the 
isoprostanes, 8-isoprostane, has been extensively investigated 
as a biomarker of oxidative stress in human disease includ-
ing lung disease (Janssen 2001; Morrow and Roberts 2002). 
8-isoprostane is a relatively abundant member of the isopros-
tanes and has been demonstrated to stimulate pulmonary 
vascular and bronchial smooth contraction in vitro (Kang et al 
1993; Kawikova et al 1996). It may therefore be important in 
the pathogenesis of COPD. There have been several recent 
reports measuring 8-isoprostane in EBC in COPD. 8-Isopros-
tane levels have been demonstrated to be higher in EBC of 
COPD patients compared with healthy controls (Montuschi 
et al 2000; Kostikas et al 2003) and levels increase further 
during exacerbations (Biernacki et al 2003). However, there 
was no correlation between 8-isoprostane levels and pul-
monary function measured as FEV1 in patients with stable 
COPD (Montuschi et al 2000; Kostikas et al 2003). Cigarette 
smoking caused an acute increase in 8-isoprostane levels 
in EBC of healthy smokers but there was no difference in 
EBC 8-isoprostane levels between current and ex-smoking 
COPD patients (Montuschi et al 2000). 8-isoprostane levels 
in EBC may, therefore, reﬂ  ect underlying airway inﬂ  amma-
tion and be an appropriate biomarker for use in larger studies 
of COPD. 8-Isoprostane may be measured in exhaled breath 
condensate using a well-validated commercially available 
enzyme immunoassay kit.
Numerous other inﬂ  ammatory mediators have been 
detected in EBC in COPD (Montuschi 2005). Additional 
biomarkers of oxidative stress, such as aldehydes, have been 
detected (Rahman et al 2002; Corradi et al 2003) but are 
unlikely to be useful clinically due to chemical instability, 
lack of speciﬁ  city, contributions from dietary sources 
and lack of speciﬁ  city and imprecision of the analytical 
methodology. EBC pH has been demonstrated to be lower 
in COPD patients compared with asthmatics and healthy 
controls and is thought to be a biomarker for airway inﬂ  am-
mation (Kostikas et al 2002). Recent reports have described 
the detection of cytokines in EBC. Interleukin-6 was 
higher in EBC of COPD patients than healthy non-smokers 
(Bucchioni et al 2003). Growth-related oncogene alpha 
levels were lower in COPD patients than non-smoking con-
trols and monocyte chemoattractant protein-1 levels were 
the same in both groups (Ko et al 2006). The signiﬁ  cance of 
these data is uncertain and cytokines were detected in EBC 
in very low quantities (pg/ml). Nonetheless, it is exciting 
that macromolecules such as cytokines can be detected in 
unconcentrated EBC and illustrates the great potential of 
EBC analysis in COPD.
New directions – collagen 
degradation products
The hallmark of emphysematous COPD is alveolar destruc-
tion. Central to this process is the destruction of structural 
proteins in the lung by proteolytic enzymes, particularly 
matrix metalloproteases (MMP’s), secreted by inﬂ  amma-
tory cells which are initially attracted to the airways by 
cigarette smoke (Shapiro and Ingenito 2005). Mice deﬁ  cient 
in MMP-12 (Hautamaki et al 1997) or neutrophil elastase 
(Shapiro et al 2003) do not develop emphysema despite 
long-term exposure to cigarette smoke and elastin degrada-
tion products have been detected in the urine of patients 
with COPD (Stone et al 1995). We have identiﬁ  ed a novel 
tripeptide, with the sequence proline-glycine-proline (PGP), 
which is a collagen breakdown product and a neutrophil 
chemoattractant (Weathington et al 2006). We have detected 
PGP in sputum and BAL ﬂ  uid (BALF) of some patients with 
COPD and cystic ﬁ  brosis but not in patients with asthma 
(Weathington et al 2006). We suspect that PGP may con-
tribute to airway inﬂ  ammation in chronic lung diseases with 
a large neutrophilic component, such as COPD and cystic 
ﬁ  brosis, and that PGP may be a biomarker for these diseases. 
Interestingly, only the COPD patients with emphysema 
detected on chest imaging were positive for PGP. Generation 
of PGP in the lung may therefore be a critical point marking 
the transition of COPD to an emphysematous phenotype. 
PGP may become a useful tool in distinguishing COPD 
from asthma and emphysematous from non-emphysematous 
COPD. PGP antagonists may be useful therapies for COPD 
directed at neutrophilic airway inﬂ  ammation.International Journal of COPD 2007:2(4) 407
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We have also detected PGP in unconcentrated EBC 
from some COPD patients using liquid chromatography 
and mass spectrometry as well as in EBC from a subset 
of healthy smokers (O’Reilly et al 2006). This means 
that PGP may enable the detection of preclinical COPD 
in at risk smokers many years before the development 
of symptoms or airflow obstruction. The combination of 
EBC collection and proteomic analysis by mass spectrom-
etry holds great promise for the noninvasive analysis of 
PGP-containing peptides and other biomarkers in COPD. 
We have detected PGP in unconcentrated BALF and EBC 
of COPD patients in similar concentrations (200–300 
pg/ml). As the dilution of ELF is much greater in EBC 
(as high as 10,000-fold) than in BALF (approximately 
100-fold), this would suggest that PGP is preferentially 
concentrated in EBC compared with BALF. There may be 
a partitioning effect with EBC collection sampling larger 
airways where PGP is generated and BAL being more 
likely to sample smaller airways and alveoli where there 
is less PGP. This may help explain why EBC has been a 
robust tool for sampling inflammatory mediators in the 
airways, as is the experience of numerous investigators, 
despite the concerns over dilution and reproducibility.
Conclusion
The analysis of exhaled breath mediators in COPD is very 
much a work in progress. ENO measurement has found its 
greatest application in the management of asthma and may 
not be as useful in COPD due to the lower levels of ENO 
found in this disease. This reﬂ  ects differences in airway 
inﬂ  ammation between asthma and COPD which are still not 
fully understood. EBC analysis is an area of great promise 
despite the problems over dilution and reproducibility. Wide-
spread adoption of this technique as a research or clinical tool 
must await the adoption of common standards and methodol-
ogy. Crucially, the true potential of EBC will not be realized 
until we have identiﬁ  ed novel biomarkers, detectable in EBC, 
that are of value in the diagnosis of COPD, identiﬁ  cation of 
preclinical disease, phenotyping of COPD patients, evaluat-
ing response to therapies and deﬁ  ning prognosis of individual 
patients. Identiﬁ  cation of novel inﬂ  ammatory mediators, 
such as PGP-containing proteins, may cast new light on the 
pathogenesis of COPD and identify new therapeutic targets, 
which are badly needed in COPD.
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